Cognition Therapeutics, Inc.
CGTX
$1.80
$0.1911.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.60M | 2.50M | 2.99M | 2.57M | 3.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.38M | 13.98M | 13.78M | 10.72M | 14.46M |
| Operating Income | -6.38M | -13.98M | -13.78M | -10.72M | -14.46M |
| Income Before Tax | -4.93M | -6.73M | -8.48M | -7.84M | -9.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.93M | -6.73M | -8.48M | -7.84M | -9.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.93M | -6.73M | -8.48M | -7.84M | -9.94M |
| EBIT | -6.38M | -13.98M | -13.78M | -10.72M | -14.46M |
| EBITDA | -6.36M | -13.96M | -13.75M | -10.70M | -14.44M |
| EPS Basic | -0.06 | -0.11 | -0.14 | -0.18 | -0.25 |
| Normalized Basic EPS | -0.04 | -0.07 | -0.09 | -0.11 | -0.15 |
| EPS Diluted | -0.06 | -0.11 | -0.14 | -0.18 | -0.25 |
| Normalized Diluted EPS | -0.04 | -0.07 | -0.09 | -0.11 | -0.15 |
| Average Basic Shares Outstanding | 77.95M | 63.69M | 61.83M | 44.68M | 40.42M |
| Average Diluted Shares Outstanding | 77.95M | 63.69M | 61.83M | 44.68M | 40.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |